Laboratory Parameters and Clinical Courses in Covid-19 Prognosis: Case Reports

Year 2022, Volume: 8 Issue: 1, 180 - 185, 25.02.2022

Mürüvvet Akçay Çelik

https://doi.org/10.19127/mbsjohs.1004209

Abstract

Coronavirus disease 2019 (COVID-19) has spread rapidly around the world since the outbreak in Wuhan, Hubei Province, China in 2019. COVID-19 is an infection caused by the novel coronavirus SARS-CoV-2.
In case 1, there were low white blood cells. In case 2, mild lung involvement was observed on his chest computed tomography. In case 3, high levels of ferritin and procalcitonin in blood parameters were found remarkably. During the COVID-19 pandemic, symptoms and laboratory parameters differ from person to person. Timely diagnosis, isolation and initiation of necessary treatments are necessary to significantly reduce the risk of disease transmission. Several biomarkers have been identified that could potentially assist risk classification models to predict severe and deadly COVID-19.

References

• Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497- 506.
• Chan JF, Yuan S, Kok KH, et al.: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 2020;395(10223):514–23.
• Kritas SK, Ronconi G, Caraffa A, et al.: Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J Biol Regul Homeost Agents. 2020;34(1).
• Lauer SA, Grantz KH, Bi Q, et al.: The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020;172:577-582.
• Wu Z, McGoogan JM: Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–42.
• Guo Y, Huang YM, Huang J, et al.: Global health governance working group for COVID-19 outbreak, institute for global health and school of public health. [COVID-19 pandemic: global epidemiological trends and China's subsequent preparedness and responses]. Zhonghua Liuxingbingxue Zazhi. 2020 March 13;41(5):643–648.
• Sun P, Qie S, Liu Z, et al.: Clinical characteristics of 50466 hospitalised patients with 2019-nCoV infection. J Med Virol. 2020 Jun;92(6):612-617.
• Guan WJ, Ni ZY, Hu Y, et al.: Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.
• Zhang C, Shi L, Wang FS: Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5:428–30.
• Chen J: Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microb Infect. 2020;22(2):69–71.
• Bassetti M, Vena A, Giacobbe DR: The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest c,irf. 2020;50(3):e13209.
• Liu Y, Yang Y, Zhang C, et al.: Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–74.
• Gutiérrez AB, Rodríguez-Morales AJ, Narváez Mejía ÁJ, et al.: Colombian consensus recommendations for diagnosis, management and treatment of the infection by SARS-CoV-2/COVID 19 in health care facilities- recommendations from expert's group based and informed on evidence. Infectio. 2020;24:1–102.
• Wang L, Li X, Chen H, et al.: Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol. 2020;51:343–348.
• Meduri GU, Headley S, Kohler G, et al.: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest. 1995;107:1062–73.
• Henry BM, De Oliveira MHS, Benoit S, et al.: Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7): 1021–1028.
• Furuta Y, Takahashi K, Kuno-Maekawa M, et al.; Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005;49:981–986.
• Tang N, Bai H, Chen X, et al.: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18:1094–1099.
• Bikdeli B, Madhavan MV, Jimenez D, et al.: COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Col Cardiol. 2020 Jun, 75 (23) 2950–2973.
• Henry BM: COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med.2020;8(4):e24.